ERBB2 and serous adenocarcinoma: Although it has been shown that ovarian cancer can overexpress HER2, minimal clinical benefit with anti-HER2 therapies has been observed in clinical trials; however, the available data derive mostly from serous carcinoma.5 Through a multiomics platform, we detected and confirmed strong HER2 expression in OCCC.